Navigation Links
Research and Development Forecast of China's Coronary Stent Industry, 2013-2017

London (PRWEB) December 05, 2013

In 2008, China finished more than 180,000 PCI surgical cases (percutaneous coronary intervention); the stent system which was used in PCI surgeries also increased to 298,000 sets in 2008 from 40,000 sets in 2002 as for the usage quantity. Since 2011, the increasingly fierce market competition has decelerated the stent system growth rate. In 2012, the usage quantity of coronary stent was about 633,600 sets and the market scale reached CNY 3.15 billion.

According to the data from the Ministry of Health, China Customs, Surgical Instrument Professional Committee of China Association for Medical Devices Industry, Chinese Society of Cardiology and some other professional associations, Huidian Research released “Research and Development Forecast of China’s Coronary Stent Industry, 2013-2017”, which mainly analyzes the market scale, demand status, competitive landscape, business performance and market share of key enterprises; on this basis, this report also provides professional investment opportunity and risk analysis, as well as scientific development prospect of the coronary stent industry.

The characteristic of this report is the summary and detailed analysis on the latest industry policy, measures and specific implementation, which can help you understanding the industry policy environment completely.

1. Overview of Coronary Stent Industry
1.1 Definition
1.2 Classification and Application
1.3 Structure of Industry Chain

2. Overview of Global Coronary Stent Market
2.1 Development Overview
2.1.1 Technical Development
2.1.2 Market Progress
2.2 Coronary Stent Market in Major Countries
2.2.1 The United States
2.2.2 Germany
2.2.3 Japan
2.3 Development Trend, 2013-2017

3. External Environment of China’s Coronary Stent Industry
3.1 China’s Macroeconomic Environment
3.1.1 Economic Development Status
3.1.2 GDP
3.1.3 Investment in the Fixed Assets
3.1.4 Total Export-Import Volume and the Growth Rate
3.2 Policy Environment
3.2.1 National Related Policies
3.2.2 Main Supervision Standards, Laws and Regulations
3.2.3 Comment on Policy Measure Implementation

4. Overall Development Status of China’s Coronary Stent Industry, 2012
4.1 Development Overview
4.1.1 Product Characteristics
4.1.2 Pricing Mechanisms
4.1.3 Marketing Channel
4.1.4 Promotion Method
4.2 Development Status
4.3 Product Price
4.3.1 Price Review, 2009-2012
4.3.2 Price Trend, 2013-2017
4.3.3 Factors Affecting the Price and the Coping Strategy
4.4 Competitive Landscape
4.4.1 Domestic Enterprises Occupy the Leading Position
4.4.2 Gaps between Domestic Enterprises and Foreign Large-scale Enterprises
4.5 Business Model

5. Import and Export of China’s Coronary Stent Industry, 2010-2012
5.1 Sources of Import and Destinations of Export
5.2 Import and Export Data, 2012
5.2.1 Import Volume
5.2.2 Import Price
5.2.3 Export Volume
5.2.4 Export Price
5.3 Forecast of Import and Export, 2013-2017
5.3.1 Import Forecast
5.3.2 Export Forecast

6. Influence of Upstream and Downstream Development on Coronary Stent Industry
6.1 Upstream Industries
6.2 Downstream User Market

7. Key Enterprises in Coronary Stent Industry
7.1 Boston Scientific
7.1.1 Company Profile
7.1.2 Business Performance
7.1.3 Competitiveness
7.1.4 Development Strategy
7.2 Medtronic
7.2.1 Company Profile
7.2.2 Business Performance
7.2.3 Mergers and Acquisitions
7.2.4 Development Strategy
7.3 Abbott
7.3.1 Company Profile
7.3.2 Business Performance
7.3.3 Competitiveness
7.3.4 Channel Development Strategy
7.4 MicroPort
7.4.1 Company Profile
7.4.2 Business Performance
7.4.3 Competitiveness
7.4.4 Development Strategy
7.5 Lepu Medical
7.5.1 Company Profile
7.5.2 Business Performance
7.5.3 Main Business
7.5.4 Competitiveness
7.5.5 Development Strategy
7.6 JW Medical Systems
7.6.1 Company Profile
7.6.2 Product Advantage
7.6.3 Business Performance
7.6.4 Scientific Research Status
7.6.5 Development Planning

8. Investment Opportunity, Value and Suggestion
8.1 Investment Opportunity
8.1.1 Balance between Supply and Demand
8.1.2 Industry Merging and Reorganization Trend
8.1.3 New Projects
8.2 Product Investment Value
8.3 Barriers to Entry
8.3.1 Technology and Process Barriers
8.3.2 Talent Barriers
8.3.3 Patent Barriers
8.3.4 Policy Barriers
8.3.5 Market Channel Barriers
8.4 Average Revenue Level
8.5 Investment Risk

9. Integrated Forecasting and Prospect of Coronary Stent, 2013-2017
9.1 Market Scale and Sales Forecast
9.2 Interpretation of Related Contents in the “Twelfth Five-Year” Plan
9.3 Conclusion and Suggestion from Experts

Companies Mentioned

Boston Scientific
Lepu Medical
JW Medical Systems

Read the full report:

Research and Development Forecast of China's Coronary Stent Industry, 2013-2017

For more information:
Sarah Smith
Research Advisor at
Tel: +44 208 816 85 48

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. UAlberta researchers uncover why combination drug treatment ineffective in cancer clinical trials
2. Researchers identify fundamental differences between human cancers and genetically engineered mouse models of cancer
3. UEA researchers receive share of £1.26 million to reduce animal experimentation for drug development
4. Oncology Leads Biosimilars Market Growth to 2018 Forecasts in New Research Report at
5. California College of Ayurveda Announces the Publication of New Research In Collaboration with UC Davis Dermatology Department on the Herb Gotu Kola
6. UCSB researcher finds origin of inherited gene mutation causing early-onset Alzheimers
7. BUSM professor receives award for Alzheimers research
8. Research on China’s Animal Vaccine Industry, 2013-2017
9. Research and Development Trend of China Independent Clinical Laboratory Market, 2013-2017
10. End-Year Special Offer on Research Studies by Current Partnering Now Available at
11. mHealth Market to Post 32.3% CAGR Through 2020, States Allied Market Research in Its Report Published at
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
Breaking Medicine Technology: